News about Global Pharma

Alembic Pharmaceuticals Secures USFDA Nod for Key GERD Injection Drug

The drug is a therapeutic equivalent to Protonix I.V., originally developed by Wyeth Pharmaceuticals, and is used to manage gastroesophageal reflux disease (GERD), erosive esophagitis, and certain rare hypersecretion conditions like Zollinger-Ellison Syndrome in adults.

Global Pharma | 02/04/2025 | By Aishwarya |  312

Freudenberg Achieves Stable Growth in 2024 with Increased Profit Margins

. Operating profit grew by about 4.7 percent, reaching EUR 1,132.4 million, up from EUR 1,081.6 million last year.

Global Pharma | 02/04/2025 | By Aishwarya |  470

Azenta Launches Automated Plate Seal Remover to Boost Lab Performance

Designed for unattended operation, the Automated Plate Seal Remover is an ideal solution for life science labs that routinely remove microplate seals.

Global Pharma | 02/04/2025 | By Aishwarya |  293

Strides Pharma Gets Recognition in S&P Global Sustainability Yearbook 2025

This recognition reflects Strides progress in integrating ESG principles across its operations.

Global Pharma | 02/04/2025 | By Aishwarya |  748

Gennova Collaborates with CEPI to Advances AI-Enhanced saRNA Vaccine for Nipah Virus

Gennova Biopharmaceuticals, a subsidiary of Emcure Pharmaceuticals, partners with Coalition for Epidemic Preparedness Innovations (CEPI) and Houston Methodist to develop an AI-enhanced saRNA vaccine for the deadly Nipah virus, securing up to USD 13.38 million for accelerated research and trials in India.

Global Pharma | 01/04/2025 | By Manvi |  447

Akums Becomes First Indian CDMO to Receive DCGI Approval for Innovative Glaucoma Treatment

Glaucoma ranks as the second leading cause of irreversible but preventable blindness worldwide, with India contributing to 23.5 percent of the global burden.

Global Pharma | 01/04/2025 | By Abha |  614

Orna Therapeutics Appoints Joseph Bolen, Ph.D., as Chief Executive Officer

Orna Therapeutics announced the appointment of Joseph Bolen, Ph.D., as Chief Executive Officer. Dr. Bolen most recently served as Orna's Chief Scientific Officer (CSO) and succeeds Amit Munshi who is stepping aside for personal reasons.

Global Pharma | 31/03/2025 | By Manvi |  213

SPARC Submits IND Application for SBO-154 to USFDA

Sun Pharma Advanced Research Company Ltd. (SPARC) has submitted an IND application to the US FDA for SBO-154, a novel antibody-drug conjugate (ADC) targeting advanced solid tumours.

Global Pharma | 31/03/2025 | By Aishwarya |  473

Spyre Therapeutics Initiates Dosing of First Participant in Phase 1 Trial of SPY003

The SPY003 Phase 1 Trial (NCT06873724) is a double-blind, placebo-controlled single-ascending dose study in healthy volunteers.

Global Pharma | 31/03/2025 | By Aishwarya |  387

IASO Bio Gets Approval of New Drug Application for Equecabtagene Autoleucel

Equecabtagene Autoleucel (FUCASO) was approved by China's National Medical Products Administration (NMPA) on June 30, 2023, for treating adult patients with relapsed or refractory multiple myeloma (R/RMM) who have received three or more lines of prior therapies, including at least one proteasome inhibitor and an immunomodulatory agent.

Global Pharma | 31/03/2025 | By Aishwarya |  263